Survey of 47 Trials Maps Cannabinoid Research in Neurology, But Evidence Gaps Remain Large

A 2025 registry-based systematic review published in Frontiers in Pharmacology catalogs 47 completed cannabinoid clinical trials across neurological conditions, revealing concentrated activity in Multiple Sclerosis, Fibromyalgia, and Parkinson’s Disease while exposing critical gaps in standardization, outcome reporting, and confirmatory evidence that prevent any conclusions about clinical efficacy.

Why This Matters

Neurological conditions such as Multiple Sclerosis, Fibromyalgia, and Parkinson’s Disease impose enormous burdens on patients and health systems, and cannabinoid-based therapies have attracted intense public and clinical interest as potential symptom-management tools. The endocannabinoid system’s known involvement in pain modulation, neuroinflammation, and motor control provides a plausible biological rationale for investigation. Mapping where clinical trial activity currently stands is essential for distinguishing genuine scientific momentum from premature therapeutic claims, particularly as patients increasingly seek cannabinoid-based treatments ahead of definitive evidence.

Clinical Summary

Interest in cannabinoids for neurological disorders has expanded considerably over the past two decades, driven by the identification of cannabinoid receptors throughout the central nervous system and preclinical data suggesting activity against neuroinflammation, spasticity, and neuropathic pain. This 2025 systematic review, published in Frontiers in Pharmacology, took a registry-based approach: rather than synthesizing published efficacy results, the authors systematically searched ClinicalTrials.gov to map the landscape of completed cannabinoid trials targeting neurological conditions. The search screened over 500,000 registry entries, narrowed to approximately 67,640 neurological trials, identified 132 cannabinoid-specific trials, and ultimately retained 47 that met inclusion criteria for completed studies using cannabinoids as a primary intervention in Phase 1 through 4 designs.

The review found that Multiple Sclerosis, Fibromyalgia, and Parkinson’s Disease were the most frequently targeted conditions, and that most trials were Phase 2, with primary outcomes centered on pain, spasticity, and cognitive function. Safety and tolerability were common secondary endpoints. Critically, no quantitative synthesis of effect sizes was performed, no formal risk-of-bias assessment was applied to the included trials, and only a single registry was searched. The authors acknowledged that non-standardized protocols, dosing regimens, and outcome measures across trials present a major barrier to drawing broader conclusions. Despite this, the paper’s conclusions include language about “promising results” and “broad therapeutic potential” that exceeds what the descriptive methodology can support. The authors call for standardized, large-scale Phase 3 trials before clinical recommendations can be made.

Dr. Caplan’s Take

This review does something genuinely useful: it tells us where the clinical trial activity is concentrated and where the gaps are. That is valuable for researchers and for clinicians trying to contextualize patient questions. But readers need to understand what this paper is not. It is not a demonstration that cannabinoids work for any neurological condition. It is a catalog of trial registrations, and the “promising” language in its conclusions outpaces its own data. When patients with MS or Parkinson’s ask me whether cannabinoids can help, I owe them honesty about the difference between active investigation and proven benefit.

In practice, I approach cannabinoid discussions for neurological symptoms with careful individualization. For patients with MS-related spasticity, there is a separate and somewhat more developed evidence base for specific formulations like nabiximols, though even that remains limited. For most other neurological applications, I counsel patients that we are still in the evidence-gathering phase and that unregulated products carry real risks of inconsistent dosing and drug interactions. I prioritize established, guideline-supported therapies first and consider cannabinoids only within a structured, monitored framework when standard options have been inadequate.

Clinical Perspective

This review sits at the very beginning of the research arc: it is a landscape survey, not an efficacy assessment. It confirms that cannabinoid research in neurology is active but immature, with the majority of completed work still at Phase 2. The absence of pooled outcomes, formal quality appraisal, and multi-registry searching means clinicians cannot use this paper to support or refute cannabinoid use for any specific neurological condition. The heterogeneity in dosing, formulations, and outcome measures across the 47 trials identified further underscores that the field has not yet converged on the methodological standards needed to produce reliable, comparable results.

From a pharmacological standpoint, clinicians considering cannabinoid therapies in neurological populations should remain alert to cytochrome P450-mediated drug interactions, particularly with antiepileptic drugs, muscle relaxants, and dopaminergic agents commonly used in these conditions. Sedation, cognitive slowing, and psychiatric side effects are relevant concerns, especially in populations already vulnerable to these outcomes. The single most actionable recommendation from this review is straightforward: do not treat “47 completed trials” as evidence of efficacy. Instead, use this mapping to identify which specific conditions have the most developed trial programs and monitor those for published Phase 3 results that might eventually change the evidence landscape.

Study at a Glance

Study Type

Registry-based systematic review (descriptive, no quantitative synthesis)

Population

Patients with neurological conditions across 47 completed trials (MS, Fibromyalgia, Parkinson’s Disease most represented)

Intervention

Cannabinoid compounds as primary intervention (various formulations and doses)

Comparator

Variable across trials; not systematically analyzed

Primary Outcomes

Pain, spasticity, cognitive function (as reported in trial registrations)

Sample Size

47 trials included; aggregate patient numbers not reported

Journal

Frontiers in Pharmacology

Year

2025

DOI or PMID

Not available from source material

Funding Source

Not reported in available text

What Kind of Evidence Is This

This is a registry-based systematic review that searched a single trial registry (ClinicalTrials.gov) to describe the characteristics of completed cannabinoid trials in neurology. It sits below traditional systematic reviews with meta-analysis in the evidence hierarchy because it performs no quantitative synthesis, applies no formal risk-of-bias tool, and draws its data from registry entries rather than published outcomes. The most important inference constraint is that this design can describe what has been studied but cannot determine whether any intervention actually works.

How This Fits With the Broader Literature

The concentration of trial activity around MS-related spasticity and pain is consistent with the existing evidence base, where nabiximols (Sativex) has accumulated the most clinical data and has achieved regulatory approval in several countries for MS spasticity. The identification of Fibromyalgia and Parkinson’s Disease as emerging areas of investigation aligns with growing preclinical interest in cannabinoid modulation of pain processing and dopaminergic pathways, respectively. However, a 2018 Cochrane review of cannabis-based medicines for chronic neuropathic pain found only modest benefits with notable adverse event rates, and a 2022 systematic review of cannabinoids in Parkinson’s Disease found insufficient evidence to support clinical use. This new mapping exercise does not alter those conclusions but does confirm that trial activity continues to expand, making it important for clinicians to track where Phase 3 confirmatory data eventually emerge.

Common Misreadings

The most likely overinterpretation is reading “47 completed trials” as equivalent to “47 trials showing cannabinoids work for neurological conditions.” This review does not report the results of those trials. It catalogs their existence in a registry. The authors’ own use of phrases such as “promising results” and “broad therapeutic potential” in their conclusions may inadvertently encourage this misreading, but those claims are based on narrative characterization and selective citation of prior literature, not on any quantitative analysis performed within this review. A second common misreading would be assuming the 47 trials represent the complete global picture; because only ClinicalTrials.gov was searched, trials registered in EU, WHO, or other international registries are absent.

Bottom Line

This review usefully maps the current clinical trial landscape for cannabinoids in neurology, confirming that MS, Fibromyalgia, and Parkinson’s Disease are the most actively studied conditions and that most work remains at Phase 2. It does not establish that cannabinoids are effective or safe for any specific neurological condition. Clinicians should treat this as a research planning tool, not as clinical evidence, and should await published Phase 3 results with rigorous outcome reporting before adjusting practice.

References

1. Registry-based systematic review of cannabinoid clinical trials for neurological conditions. Frontiers in Pharmacology, 2025. (Primary article; DOI not available from source material.)
2. Mucke M, Phillips T, Radbruch L, Petzke F, Hauser W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews, 2018. DOI: 10.1002/14651858.CD012182.pub2
3. Defined daily doses and clinical evidence for nabiximols (Sativex) in MS spasticity. Multiple regulatory submissions and associated trial publications; see European Medicines Agency product summaries.
4. Defined systematic reviews of cannabinoids in Parkinson’s Disease, 2022. (Referenced contextually; specific DOI not available from source material.)